Evidence map›Paper›PMID 35973601›Full record

ReviewNeuropharmacology2022

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines.

Sean J Belouin, Lynnette A Averill, Jack E Henningfield, Stephen N Xenakis, Ingrid Donato, Charles S Grob, Ann Berger, Veronica Magar, Alicia L Danforth, Brian T Anderson

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Review
  3. Trials, trips, and tribulations: pathways for implementing psychedelic therapy in Ireland.The international journal of neuropsychopharmacology · 2026
    Review
  4. Review
  5. Review
  6. Ethical Aspects of Psychedelic-Assisted Treatments: An Overview.Current topics in behavioral neurosciences · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians' Concerns.The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sean J BelouinUnited States Public Health Service, Germantown, MD, USA; Substance Abuse and Mental Health Services Administration (SAMHSA), Rockville, MD, USA; Pain and Palliative Care, NIH Clinical Research Center, Bethesda, MD, USA. Electronic address: sjbelouin@gmail.com.
Lynnette A AverillMenninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; US Department of Veterans Affairs, Michael E. DeBakey Veterans Administration Medical Center, Houston, TX, USA; Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA; US Department of Veterans Affairs, National Center for PTSD - Clinical Neurosciences Division, Orange, CT, USA; Reason for Hope, New York, NY, USA.
Jack E HenningfieldDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Research, Health Policy and Abuse Liability, Pinney Associates, Bethesda, MD, USA.
Stephen N XenakisReason for Hope, New York, NY, USA; United States Army, Hallandale Beach, FL, USA; Uniformed Services University of the Health Sciences (UHSUS), Bethesda, MD, USA.
Ingrid DonatoOffice of Prevention Innovation, Center for Substance Abuse Prevention, SAMHSA, Rockville, MD, USA.
Charles S GrobDavid Geffen School of Medicine at University of California (UCLA), Los Angeles, CA, USA; Division of Child and Adolescent Psychiatry, Harbor-UCLA Medical Center, Torrance, CA, USA.
Ann BergerPain and Palliative Care, NIH Clinical Research Center, Bethesda, MD, USA.
Veronica MagarGender, Equity and Human Rights, World Health Organization (WHO), Geneva, Switzerland.
Alicia L DanforthThe Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, USA.
Brian T AndersonUniversity of California San Francisco (UCSF) Department of Psychiatry & Behavioral Sciences, San Francisco, CA, USA; University of California Berkeley Center for the Science of Psychedelics, Berkeley, CA, USA.

Funding

Intramural NIH HHS Z99 CL999999World Health Organization 001
6 · The paper itself

Abstract

There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food and Drug Administration and may potentially receive full FDA approval with similar regulatory considerations occurring in multiple countries. At the same time, regulatory changes are poised to increase access to legal or decriminalized psychedelic use in various non-medical settings. This review provides a brief discussion on the historical use of psychedelic medicines, the status of the empirical evidence, and numerous significant policy considerations that must be thoughtfully addressed regarding standards-of-practice, consumer protection, engagement of communities, safeguarding access for all, and developing data standards, which supports the responsible, accountable, safe, and ethical uses of these medicines in clinical, faith-based, and other contexts. We provide suggestions for how public health and harm reduction can be supported through a public-private partnership that engages a community of stakeholders from various disciplines in the co-creation and dissemination of best practices and public policies.

Indexed as

HallucinogensN-Methyl-3,4-methylenedioxyamphetamineSubstance Withdrawal SyndromeHumansPolicyPsilocybinHallucinogensN-Methyl-3,4-methylenedioxyamphetaminePsilocybinHallucinogenHarm reductionMDMAPolicyPsilocybinPsychedelic

Identifiers

PMID35973601
PMCPMC9536012

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.